Oncodistinct trials investigate existing and new therapies in all settings and are not dedicated to a specific trial phase or tumor type with a focus on:
Open-label, phase II, non-randomized basket trial.
Basket trial to assess the efficacy of abemaciclib in multiple platinum-resistant tumour types by using metabolic imaging (PERCIST) and RECIST v1.1 criteria.
Find more on the scientific rationale here: https://vimeo.com/351181211
Open-label, phase II, multicentre, randomized trial.
This trial aims to assess the safety and efficacy of Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer. Pembrolizumab is administered every 3 weeks during the neoadjuvant chemotherapy. The primary endpoint is pathological complete response.
Open-label, phase II, interventional, multi-centre, randomized trial.
Open-label, phase II, interventional, multi-centre, randomized trial.
The trial aims to evaluate Avelumab in combination with standard folfox chemotherapy following short course radiation therapy as neoadjuvant treatment for locally advanced rectal cancer patients. The primary endpoint is pathological complete response.
ESMO presentation can be found here.
Tackling the challenge of CNS metastases
Building a multidisciplinary Brain Metastases Clinical Research Platform called BrainStorm. The BrainStorm program will focus on patients with newly diagnosed non-CNS metastatic solid tumors with high risk of developing CNS metastases and will allow building a large clinico pathological database for CNS metastases including ctDNA analyzes from CSF samples. Substudies will be proposed at each time-period with the final objective to develop innovative treatment approaches and strategies.
A phase II trial of neoadjuvant Regorafenib in combination with Nivolumab and short-course radiotherapy in intermediate-risk, stage II-III rectal cancer.
The trial aims to evaluate the efficacy of the combination of nivolumab and regorafenib when administered before and after standard, pre-operative short-course radiation therapy.
A phase I first in human study of the anti CD73, IPH5301 in combination with chemotherapy with or without trastuzuman in patients with advanced solid tumors.
The trial aims to evaluate the occurrence of dose limiting toxicity (DLT) of IPH5301 in monotherapy in the dose escalation and in combination with paclitaxel and trastuzumab in the expansion cohort.
ONCODISTINCT. Accelerating Oncology drug Development and Innovative strategies in Clinical Trials
© Oncodictinct 2024 – Privacy policy